TD Asset Management Inc Purchases Shares of 39,876 Beta Bionics, Inc. (NASDAQ:BBNX)

TD Asset Management Inc purchased a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 39,876 shares of the company’s stock, valued at approximately $488,000. TD Asset Management Inc owned approximately 0.09% of Beta Bionics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BBNX. Rhumbline Advisers acquired a new position in Beta Bionics during the first quarter valued at approximately $158,000. Bank of New York Mellon Corp acquired a new position in Beta Bionics during the first quarter valued at approximately $316,000. Values First Advisors Inc. acquired a new position in Beta Bionics during the first quarter valued at approximately $457,000. Evanson Asset Management LLC acquired a new position in Beta Bionics during the first quarter valued at approximately $475,000. Finally, Jennison Associates LLC acquired a new position in Beta Bionics during the first quarter valued at approximately $828,000.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BBNX shares. Robert W. Baird set a $17.00 price target on shares of Beta Bionics and gave the company a “neutral” rating in a research report on Wednesday, July 30th. Lake Street Capital started coverage on shares of Beta Bionics in a research note on Thursday, June 12th. They set a “buy” rating and a $30.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of Beta Bionics in a research note on Friday, May 30th. They set a “neutral” rating and a $16.00 price objective on the stock. Truist Financial lifted their price objective on shares of Beta Bionics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. Finally, Wolfe Research started coverage on shares of Beta Bionics in a research note on Friday, May 30th. They set an “outperform” rating and a $20.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.56.

Beta Bionics Price Performance

Shares of NASDAQ:BBNX opened at $16.42 on Tuesday. The stock has a fifty day moving average of $15.79. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $24.50.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, July 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.12. The business had revenue of $23.24 million for the quarter, compared to the consensus estimate of $19.73 million.

Insider Activity at Beta Bionics

In other news, CFO Stephen Feider sold 1,497 shares of the company’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $26,781.33. Following the completion of the transaction, the chief financial officer owned 45,503 shares in the company, valued at approximately $814,048.67. This represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 4,519 shares of company stock worth $80,845 in the last three months.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.